1型固有淋巴细胞参与实验性抗GBM肾小球肾炎进展并受PPARα调控
研究在Wistar Kyoto大鼠抗GBM肾小球肾炎模型中鉴定肾小球浸润的CD8+非T淋巴细胞为1型固有淋巴细胞,其高表达IFN-γ和T-bet。PPARα激动剂可减轻肾损伤并降低相关细胞因子和趋化因子表达,体外实验显示PPARα激动剂抑制固有淋巴细胞产生IFN-γ及IFN-γ诱导的内皮细胞和足细胞趋化因子表达,人抗GBM肾炎肾小球中也检测到固有淋巴细胞浸润。
要点
- 肾小球浸润的CD8+非T淋巴细胞为1型固有淋巴细胞,高表达IFN-γ和T-bet。
- PPARα激动剂减轻实验性抗GBM肾炎肾损伤并降低IFN-γ、TNF-α及CXCL9/10/11表达。
- 固有淋巴细胞可能成为抗GBM肾小球肾炎的新治疗靶点。
核心结论
- 1型固有淋巴细胞参与抗GBM肾小球肾炎进展,并直接或间接受PPARα调控。
研究设计与样本
- 研究采用Wistar Kyoto大鼠抗GBM肾小球肾炎模型,并检测人抗GBM肾小球肾炎肾小球中固有淋巴细胞浸润。
主要发现
- 肾小球浸润的CD8+非T淋巴细胞为谱系阴性细胞,高表达IFN-γ和T-bet mRNA而不表达Eomes,提示为1型固有淋巴细胞。
- 抗GBM肾炎中肾小球IFN-γ、TNF-α及CXCL9、CXCL10、CXCL11 mRNA显著增加。
- PPARα激动剂治疗改善肾损伤并降低上述mRNA表达。
- 体外IL-12和IL-18刺激增强固有淋巴细胞IFN-γ产生,PPARα激动剂可减少该产生。
- IFN-γ上调肾小球内皮细胞CXCL9 mRNA及足细胞和巨噬细胞CXCL9、CXCL10、CXCL11 mRNA,PPARα激动剂下调其表达。
临床怎么用
- PPARα激动剂可能通过抑制1型固有淋巴细胞及IFN-γ相关趋化因子通路减轻抗GBM肾炎肾损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Innate lymphoid cells play an important role in the early effector cytokine-mediated response. In Wistar Kyoto rats, CD8+ non-T lymphocytes (CD8+Lym) infiltrate into glomeruli during the development of anti-glomerular basement membrane (anti-GBM) glomerulonephritis. Here, we examined the profiles and roles of CD8+Lym in anti-GBM glomerulonephritis. The regulation of CD8+Lym by peroxisome proliferator-activated receptor (PPAR)-α in anti-GBM glomerulonephritis was also evaluated. Glomerular infiltrating CD8+Lym were lineage-negative cells that showed markedly high expression of IFN-γ and T-bet mRNAs but not Eomes, indicating these cells are group 1 innate lymphoid cells. In anti-GBM glomerulonephritis, the glomerular mRNAs of innate lymphoid cell-related cytokines (IFN-γ and TNF-α) and chemokines (CXCL9, CXCL10, and CXCL11) are significantly increased. Treatment with a PPARα agonist ameliorated renal injury, with reduced expression of these mRNAs. In vitro, enhanced IFN-γ production from innate lymphoid cells upon IL-12 and IL-18 stimulation was reduced by the PPARα agonist. Moreover, CXCL9 mRNA in glomerular endothelial cells and CXCL9, CXCL10, and CXCL11 mRNAs in podocytes and macrophages were upregulated by IFN-γ, whereas the PPARα agonist downregulated their expression. We also detected the infiltration of innate lymphoid cells into glomeruli in human anti-GBM glomerulonephritis. Thus, innate lymphoid cells are involved in the progression of anti-GBM glomerulonephritis and regulated directly or indirectly by PPARα. Our findings suggest that innate lymphoid cells could serve as novel therapeutic targets for anti-GBM glomerulonephritis.
引用
- Okabayashi Y, Nagasaka S, Kanzaki G, et al. Group 1 innate lymphoid cells are involved in the progression of experimental anti-glomerular basement membrane glomerulonephritis and are regulated by peroxisome proliferator-activated receptor α. Kidney Int. 2019. PMID: 31402171. doi:10.1016/j.kint.2019.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。